Yahoo
    Stuttgart - Delayed Quote EUR

    NurExone Biologic Inc (J90.SG)

    0.2940 -0.0020 (-0.68%)
    As of 8:48:40 AM GMT+1. Market Open.
    Loading Chart for J90.SG
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

    NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
    GlobeNewswire 1mo ago
    NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications

    NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
    GlobeNewswire 1mo ago
    NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership

    NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
    GlobeNewswire 2mo ago
    NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness

    NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
    GlobeNewswire 3mo ago
    NurExone Announces Closing of Non-Brokered Private Placement

    NurExone Announces Closing of Non-Brokered Private Placement
    GlobeNewswire 4mo ago
    NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

    NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
    GlobeNewswire 5mo ago
    NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes

    NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
    GlobeNewswire 9d ago
    NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth

    NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth
    GlobeNewswire 17d ago
    NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results

    NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
    GlobeNewswire 30d ago
    NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

    NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
    GlobeNewswire 1mo ago
    NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

    NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing
    InvestorsHub 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: